| Literature DB >> 29740493 |
Ming-Rong Cao1, Ze-Ping Han2, Ji-Ming Liu1, Yu-Guang Li2, Yu-Bing Lv2, Jia-Bin Zhou2, Jin-Hua He2.
Abstract
Computational analysis and bioinformatics have significantly advanced the ability of researchers to process and analyze biological data. Molecular data from human and model organisms may facilitate drug target validation and identification of biomarkers with increased predictive accuracy. The aim of the present study was to investigate the function of long non-coding RNAs (lncRNAs) in hepatocellular carcinoma (HCC) using online databases, and to predict their regulatory mechanism. HCC-associated lncRNAs, their downstream transcription factors and microRNAs (miRNAs/miRs), as well as the HCC-associated target genes, were identified using online databases. HCC-associated lncRNAs, including HOX antisense intergenic RNA (HOTAIR) and metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) were selected based on established databases of lncRNAs. The interaction between the HCC-associated lncRNAs and miRNAs (hsa-miR-1, hsa-miR-20a-5p) was predicted using starBase2.0. Signal transducer and activator of transcription 1, hepatocyte nuclear factor 4α (HNF4A), octamer-binding transcription factor 4, Nanog homeobox (NANOG), caudal type homeobox 2 (CDX2), DEAD-box helicase 5, brahma-related gene 1, MYC-associated factor X and MYC proto-oncogene, bHLH transcription factor have been identified as the transcription factors for HOTAIR and MALAT1 using ChIPBase. Additionally, CDX2, HNF4A, NANOG, ETS transcription factor, Jun proto-oncogene and forkhead box protein A1 were identified as the transcription factors for hsa-miR-1 and hsa-miR-20a-5p. CDX2, HNF4A and NANOG were the transcriptional factors in common between the lncRNAs and miRNAs. Cyclin D1, E2F transcription factor 1, epithelial growth factor receptor, MYC, MET proto-oncogene, receptor tyrosine kinase and vascular endothelial growth factor A were identified as target genes for the HCC progression, two of which were also the target genes of hsa-miR-1 and hsa-miR-20a-5p using the miRwalk and OncoDN. HCC databases. Additionally, these target genes may be involved in biological functions, including the regulation of cell growth, cell cycle progression and mitosis, and in disease progression, as demonstrated using DAVID clustering analysis. The present study aimed to predict a regulatory network of lncRNAs in HCC progression using bioinformatics analysis.Entities:
Keywords: bioinformatics; hepatocellular carcinoma; long non-coding RNA; regulation network
Year: 2018 PMID: 29740493 PMCID: PMC5934726 DOI: 10.3892/ol.2018.8271
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Hepatocellular carcinoma-associated lncRNAs obtained from the lncRNA disease database.
| lncRNA | Dysfunction type | Chromosome | Genbank |
|---|---|---|---|
| H19 | Expression | 11 | NR_002196.1 |
| Expression | 11 | NR_002196.48 | |
| N/A | 11 | NR_002196.17 | |
| Expression | 11 | NR_002196.1 | |
| Regulation | 11 | NR_002196.1 | |
| HEIH | Expression | 5 | NR_045680.1 |
| HOTAIR | Expression | 12 | NR_047517.1 |
| Expression | 12 | NR_047517.10 | |
| Expression | 12 | NR_047517.13 | |
| Expression | 12 | NR_047517.3 | |
| Expression | 12 | NR_047517.1 | |
| Expression | 12 | NR_047517.15 | |
| Regulation | 12 | NR_047517.1 | |
| HOTTIP | Expression | 7 | NR_037843.3 |
| Expression | 7 | NR_037843.3 | |
| Expression | 7 | NR_037843.2 | |
| HULC | Expression | 6 | NR_004855.2 |
| Regulation | 6 | NR_004855.2 | |
| Regulation | 6 | NR_004855.2 | |
| Expression | 6 | NR_004855.3 | |
| Expression | 6 | NR_004855.4 | |
| Expression | 6 | NR_004855.6 | |
| Expression | 6 | NR_004855.2 | |
| Regulation | 6 | NR_004855.2 | |
| IGF2-AS | N/A | 11 | NR_028044.1 |
| KCNQ1OT1 | Mutation | 11 | NR_002728.3 |
| MALAT1 | Expression | 11 | NR_002819.2 |
| Expression | 11 | NR_002819.2 | |
| Expression | 11 | NR_002819.7 | |
| Expression | 11 | NR_002819.12 | |
| Expression | 11 | NR_002819.17 | |
| Mutation | 11 | NR_002819.5 | |
| Expression | 11 | NR_002819.2 | |
| MEG3 | Expression | 14 | NR_002766.2 |
| Expression | 14 | NR_002766.15 | |
| Regulation | 14 | NR_002766.2 | |
| MINA | Expression | 3 | XR_241516.2 |
| MIR7-3HG | Expression | 19 | NR_027148.1 |
| NPTN-IT1 | Expression | 15 | AK055007.1 |
| Expression | 15 | AK055007.1 |
HCC, hepatocellular carcinoma; lncRNA, long non-coding RNA; HEIH, hepatocellular carcinoma upregulated EZH2-associated long non-coding RNA HOTAIR, HOX transcript antisense RNA; HOTTIP, HOXA distal transcript antisense RNA; HULC, highly upregulated in liver cancer; IGF2-AS, insulin-like growth factor 2-antisense RNA; KCNQ1OT1, KCNQ1 overlapping transcript 1; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MEG3, maternally expressed 3; MINA, MYC induced nuclear antigen; MIR7-3HG, MIR7-3 host gene; NPTN-IT1, NPTN intronic transcript 1; N/A, not available.
Figure 1.(A) Location of the target lncRNAs and their (B) expression pattern in different tissue. lncRNAs, long non-coding RNAs; HOTAIR, HOX antisense intergenic RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; Chr, chromosome; HULC, highly upregulated in liver cancer; wbc, whole blood cells.
Figure 2.Prediction of interaction between MALAT1/HOTAIR and miRNAs. HOTAIR, HOX antisense intergenic RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; miRNA/miR, microRNA.
Figure 3.HCC-associated miRNAs. HCC, hepatocellular carcinoma; miRNA/miR, microRNA.
Figure 4.Prediction of transcription factors for the lncRNAs MALAT1 and HOTAIR. lncRNAs, long non-coding RNAs; HOTAIR, HOX antisense intergenic RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1.
Figure 5.Prediction of transcription factors for the target miRNAs (hsa-miR-1 and hsa-miR-20a-5p). miRNA/miR, microRNA.
Figure 6.HCC-associated transcription factors for the target miRNAs and lncRNAs. miRNA/miR, microRNA; HCC, hepatocellular carcinoma; lncRNAs, long non-coding RNAs.
Figure 7.Shared target genes between hsa-miR-1 and hsa-miR-20a-5p obtained from the miRWalk database. miR, microRNA.
HCC-associated miRNA target genes obtained from the OncoDB.HCC database.
| Gene | Description | Evidence |
|---|---|---|
| CCND1 | G1/S-specific cyclin-D1 (PRAD1 oncogene) | Arrays: C.R.01a, PNAS01, MBC 02 |
| (BCL-1 oncogene). [Source: Uniprot/SWISSPROT; Acc: P24385] | Experiments: upregulated (RT-PCR, IHC and western blotting) | |
| E2F1 | Transcription factor E2F1 (E2F-1) (Retinoblastoma-binding protein 3) (RBBP-3) (PRB-binding protein E2F-1) (PBR3) (Retinoblastoma-associated protein 1) (RBAP-1). | Experiments: upregulated (RT-PCR) |
| [Source: Uniprot/SWISSPROT; Acc: Q01094] | ||
| EGFR | Epidermal growth factor receptor precursor (EC 2.7.10.1) | Experiments: upregulated (IHC) |
| (Receptor tyrosine-protein kinase ErbB-1). [Source: Uniprot/SWISSPROT; Acc: P00533] | ||
| MYC | Myc proto-oncogene protein (c-Myc) (Transcription factor p64). [Source: Uniprot/SWISSPROT; Acc: P01106] | Arrays: PNAS01, Onc. 02, MBC 02 Experiments: upregulated (RT-PCR and IHC) |
| NOS2A | Nitric oxide synthase, inducible (EC 1.14.13.39) (NOS type II) (Inducible NO synthase) (Inducible NOS) (iNOS) (Hepatocyte NOS) (HEP-NOS). | Experiments: upregulated (RT-PCR) |
| [Source: Uniprot/SWISSPROT; Acc: P35228] | ||
| VEGFA | Vascular endothelial growth factor A precursor (VEGF-A) (Vascular permeability factor) (VPF). [Source: Uniprot/SWISSPROT; Acc: P15692] | Experiments: upregulated (Northern blotting and IHC) |
| MET | Hepatocyte growth factor receptor precursor (EC 2.7.10.1) | Experiments: upregulated (RT-PCR and mutation) |
| (HGF receptor) (Scatter factor receptor) (SF receptor) (HGF/SF receptor) (Met proto-oncogene tyrosine kinase) (c-Met). | ||
| [Source: Uniprot/SWISSPROT; Acc: P08581] | ||
| CDKN1A | Cyclin-dependent kinase inhibitor 1 (p21) (CDK-interacting protein 1) (Melanoma differentiation-associated protein 6) | Arrays: Gast01, Onc.02, J.H.03 Experiments: downregulated (IHC and RT-PCR) |
| (MDA-6). [Source: Uniprot/SWISSPROT; Acc: P38936] | ||
| NPM1 | Nucleophosmin (NPM) (Nucleolar phosphoprotein B23) | Arrays: PNAS01, MBC02, CCR03, Prot05a, Prot05c |
| (Numatrin) (Nucleolar protein NO38). [Source: Uniprot/SWISSPROT; Acc: P06748] | ||
| THBS1 | Thrombospondin-1 precursor. [Source: Uniprot/SWISSPROT; Acc: P07996] | Experiments: downregulated (qPCR) |
| TP53 | Cellular tumor antigen p53 (Tumor suppressor p53) (Phosphoprotein p53) (Antigen NY-CO-13). | Experiments: other (IHC, western blotting, mutation and methylation) |
| [Source: Uniprot/SWISSPROT; Acc: P04637] |
HCC, hepatocellular carcinoma; miR, microRNA; RT-PCR, reverse transcription-polymerase chain reaction; IHC, immunohistochemistry; qPCR, quantified polymerase chain reaction.
GO enrichment analysis for the seven HCC-associated miRNA target genes.
| GO ID | Term | Genes | Percentage[ | P-value | Benjamini[ |
|---|---|---|---|---|---|
| GO:0008283 | Cell proliferation | E2F1, EGFR, MET, MYC, VEGFA | 83.3 | 5.20×10−6 | 2.40×10−3 |
| GO:0051726 | Regulation of cell cycle | E2F1, CCND1, EGFR, MYC | 66.7 | 1.40×10−4 | 3.20×10−2 |
| GO:0008284 | Positive regulation of cell proliferation | CCND1, EGFR, MYC, VEFA | 66.7 | 2.70×10−4 | 4.10×10−2 |
| GO:0044093 | Positive regulation of molecular function | CCND1, EGFR, MET, MYC | 66.7 | 7.60×10−4 | 4.20×10−2 |
| GO:0009891 | Positive regulation of biosynthetic process | E2F1, EGFR, MYC, VEGFA | 66.7 | 1.20×10−3 | 4.30×10−2 |
| GO:0022402 | Cell cycle process | E2F1, CCND1, EGFR, MYC | 66.7 | 6.80×10−4 | 4.40×10−2 |
| GO:0051325 | Interphase | E2F1, CCND1, EGFR | 50 | 6.00×10−4 | 4.50×10−2 |
| GO:0007346 | Regulation of mitotic cell cycle | CCND1, EGFR, MYC | 50 | 1.20×10−3 | 4.60×10−2 |
| GO:0031328 | Positive regulation of cellular biosynthetic process | E2F1, EGFR, MYC, VEGFA | 66.7 | 1.20×10−3 | 4.90×10−2 |
Percentage of target genes from current functional annotation that are total target genes
Benjamini-corrected P-value. HCC, hepatocellular carcinoma; miR, microRNA; GO, gene ontology.
KEGG pathway enrichment analysis for the seven HCC-associated miRNA target genes.
| KEGG ID | Term | Genes | Percentage[ | P-value | Benjamini[ |
|---|---|---|---|---|---|
| hsa05219 | Bladder cancer | E2F1, CCND1, EGFR, MYC, VEGFA | 83.3 | 2.00×10−8 | 7.00×10−7 |
| hsa05200 | Pathways in cancer | E2F1, CCND1, EGFR, MET, MYC, VEGFA | 100 | 1.10×10−6 | 1.90×10−5 |
| hsa05218 | Melanoma | E2F1, CCND1, EGFR, MET | 66.7 | 2.60×10−5 | 3.00×10−4 |
| hsa05212 | Pancreatic cancer | E2F1, CCND1, EGFR, VEGFA | 66.7 | 2.70×10−5 | 2.30×10−4 |
| hsa05210 | Colorectal cancer | CCND1, EGFR, MET, MYC | 66.7 | 4.20×10−5 | 3.00×10−4 |
| hsa04510 | Focal adhesion | CCND1, EGFR, MET, VEGFA | 66.7 | 5.70×10−4 | 3.30×10−3 |
| hsa05213 | Endometrial cancer | CCND1, EGFR, MYC | 50 | 1.00×10−3 | 5.00×10−3 |
| hsa05223 | Non-small cell lung cancer | E2F1, CCND1, EGFR | 50 | 1.10×10−3 | 4.70×10−3 |
| hsa05214 | Glioma | E2F1, CCND1, EGFR | 50 | 1.50×10−3 | 5.70×10−3 |
| hsa05220 | Chronic myeloid leukemia | E2F1, CCND1, MYC | 50 | 2.10×10−3 | 7.30×10−3 |
| hsa05222 | Small cell lung cancer | E2F1, CCND1, MYC | 50 | 2.60×10−3 | 8.30×10−3 |
| hsa05212 | Prostate cancer | E2F1, CCND1, EGFR | 50 | 2.90×10−3 | 8.50×10−3 |
| hsa04110 | Cell cycle | E2F1, CCND1, MYC | 50 | 5.70×10−3 | 1.50×10−2 |
Percentage of target genes from current functional annotation that are total target genes
Benjamini-corrected P-value. HCC, hepatocellular carcinoma; miR, microRNA; KEGG, Kyoto Encyclopedia of Genes and Genomes.
Figure 8.Prediction of the number of the transcription factors for the six target genes using ConSite. CCND1, cyclin D1; E2F1, E2F transcription factor 1; EGFR, epithelial growth factor receptor; MYC, MYC proto-oncogene, bHLH transcription factor; MET, MET proto-oncogene, receptor tyrosine kinase; VEGFA, vascular endothelial growth factor A.
Prediction of the overlapping transcription factors for the six target genes using ConSite.
| Transcription factor | Sequence | From (position) | To (position) | Score |
|---|---|---|---|---|
| Hunchback | TTTTTTATGC | 6,433 | 6,442 | 12.824 |
| AML-1 | TTTGTGGTT | 2,631 | 2,639 | 12.626 |
| c-REL | GGGGTTTTCC | 8,856 | 8,865 | 12.159 |
| E74A | CCGGAAG | 6,379 | 6,385 | 10.755 |
| Snail | CAGGTG | 2,151 | 2,156 | 10.744 |
| Thing1-E47 | GGTCTGGCTT | 1,529 | 1,538 | 12.164 |
TF, transcription factor; AML-1, acute myeloid leukemia protein-1; c-REL, proto-oncogene c-Rel; E74A, ETS transcription factor E74A.
Figure 9.Proposed functional regulatory network of lncRNA in HCC. miR, microRNA; HCC, hepatocellular carcinoma; lncRNA, long non-coding RNA.